Novo Nordisk launches Xultophy diabetes therapy in U.S.

Novo Nordisk (NYSE:NVO) said today that it launched its Type II diabetes combination therapy, Xultophy, in pharmacies across the U.S. The injection is a combination of insulin degludec and liraglutide that is indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type II diabetes. In clinical trials, Xultophy reduced A1C and lowered blood sugar for 24 hours, according to Nordisk. Get the full story at our sister site, Drug Delivery Business News. The post Novo Nordisk launches Xultophy diabetes therapy in U.S. appeared first on MassDevice.
Source: Mass Device - Category: Medical Equipment Authors: Tags: Diabetes Drug-Device Combinations Pharmaceuticals Wall Street Beat Novo Nordisk Source Type: news